Search
for
Sort by
Research 151–180 of 334
- Medications Most Commonly Associated With Erectile Dysfunction: Evaluation of the Food and Drug Administration National Pharmacovigilance Database
- The clinical applications of five-alpha reductase inhibitors.
- Serenoa repens induced erectile dysfunction: Underdiagnosis and phytovigilance
- Re: Can Long-Term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?
- Further research needed if finasteride is to become standard of care for frontal fibrosing alopecia (FFA)
- Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review
- Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model
- Post-finasteride syndrome: survey of dermatologists from the Spanish Hair and Nail Disorders Group
- Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
- The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
- Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
- Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
- LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
- The Frontal Fibrosing Alopecia Treatment Dilemma
- Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects
- Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
- PD49-02 MEDICATIONS MOST COMMONLY ASSOCIATED WITH ERECTILE DYSFUNCTION: EVALUATION OF THE FOOD AND DRUG ADMINISTRATION NATIONAL PHARMACOVIGILANCE DATABASE
- Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial
- Editorial Comment
- Slow progress in prostate cancer
- US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
- Dutasteride for Androgenetic Alopecia: Review Article
- 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database
- Post-Finasteride Syndrome (PFS) Update: Point/Counterpoint
- The impact of monotherapies for male androgenetic alopecia: A network meta‐analysis study
- Outcome of Dutasteride 0.5mg in Androgenic Alopecia
- 5α- Reductase Inhibitors in Prostate Cancer: An Overview
- Low-dose finasteride in benign prostatic hyperplasia: a comprehensive narrative review of efficacy, safety, and preventative potential
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Using 5 alpha reductase inhibitors safely: What primary care physicians need to know